Please assess the completion status of the following clinical trial:

Trial Title: Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have locally advanced (unresectable) or metastatic, well or moderately differentiated pancreatic endocrine tumors.~* Measurable disease on CT scan or MRI.~* Age ≥ 18 years and ≤ 80 years.~* Use of effective means of contraception (men and women) in subjects of child-bearing potential~* Adequate renal function (serum creatinine ≤1.5, urine protein:creatinine ratio \<1.0 or urine dipstick for proteinuria \< 2+ (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1 g of protein in 24 hours to be eligible).~* Adequate hepatic function (bilirubin ≤2.0, AST and ALT ≤ 3x ULN.~* Adequate hematologic function (WBC ≥ 3,000, ANC ≥ 1500, platelets ≥ 100,000)~Exclusion Criteria:~* Prior therapy with fluorouracil, doxorubicin, streptozocin or avastin~* Ejection fraction on MUGA \<50%~* ECOG performance status \> 2~* Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored avastin cancer study~* Inadequately controlled hypertension (defined as systolic blood pressure \>150 and/or diastolic blood pressure \> 100 mmHg on antihypertensive medications)~* Any prior history of hypertensive crisis or hypertensive encephalopathy~* Unstable angina~* New York Heart Association (NYHA) Grade II or greater congestive heart failure~* History of myocardial infarction or unstable angina within 6 months prior to study enrollment~* History of stroke or transient ischemic attack within 6 months prior to study enrollment~* Significant vascular disease (e.g., aortic aneurysm, aortic dissection)~* Symptomatic peripheral vascular disease~* Evidence of bleeding diathesis or coagulopathy~* Presence of central nervous system or brain metastases~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study~* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment~* Pregnant (positive pregnancy test) or lactating. Use of effective means of contraception (men and women) in subjects of child-bearing potential~* Proteinuria at screening as demonstrated by either~  * Urine protein: creatinine (UPC) ratio ≥ 1.0 at screening OR~ * Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0~* Evidence of duodenal invasion on CT scan, MRI, or endoscopy~* Known hypersensitivity to any component of avastin~* Serious, non-healing wound, ulcer, or bone fracture~* Inability to comply with study and/or follow-up procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Protocol Specified Chemotherapy (Type: EXPERIMENTAL): Protocol Specified Chemotherapy Every 28 Days: Avastin, Fluorouracil, Doxorubicin, Streptozocin.~Premedications: Dexamethasone, Ondansetron

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy